AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Company to launch Femprox clinical study in China.
2004 APR 1 - (NewsRx.com & NewsRx.net) -- NexMed, Inc., (NEXM), a developer of transdermal treatments based on its proprietary drug delivery technology, announced its plans to initiate a 400-patient phase III study for Femprox in China.
The design of this study is based on results from NexMed's clinical studies to date, and is double-blind, placebo-controlled, and randomized, and will test the efficacy and safety of Femprox cream in patients diagnosed with female sexual arousal disorder (FSAD).
Femprox is topically applied, and incorporates alprostadil, a vasodilator that is administered through the NexACT transdermal enhancer. In NexMed's U.S. phase II study for Femprox, 98 premenopausal women diagnosed with FSAD completed the 4-week clinical study in an "at-home" setting. The trial results demonstrated positive dose-related trends, with up to 77% mean percent success rate reported at the highest dose vs. 55% reported for the placebo. The side effects observed in the study were mild in nature and short in duration.
These results were presented at the 2002 annual meeting of the American Urological Association and were published in the ...
- NexMed announces Femprox license agreement for South Korea.
- Magazine article from: Women's Health Weekly March 18, 2004 700+ words
...product in our country." Femprox incorporates NexMed's NexACT...s first phase II study of Femprox were published in the October...the efficacy and safety of Femprox cream in 94 premenopausal...was prepared by Women's Health Weekly editors from staff and other...
- Fifth patent allowed for Femprox.
- Magazine article from: Women's Health Weekly June 3, 2004 700+ words
...innovative technology." Femprox is topically applied, and...patient phase 3 study for Femprox in China. This study is double...the efficacy and safety of Femprox cream in patients diagnosed...was prepared by Women's Health Weekly editors from staff and other...
- NexMed Announces Femprox(R) License Agreement for South Korea; - Femprox(R) in...
- Press release article from: PR Newswire February 19, 2004 700+ words
...pharmaceuticals companies in South Korea, has licensed Femprox(R) for Korea. Femprox(R) is NexMed's proprietary cream treatment...develop and obtain regulatory approval to market Femprox(R) in South Korea, and NexMed, through its...
- NexMed Announces Positive Femprox Study Results at AUA Annual Meeting in San...
- Press release article from: PR Newswire May 23, 2005 700+ words
...efficacy and safety of three strengths of the Femprox(R) cream in pre-menopausal and post...sexual arousal disorder ("FSAD"). Femprox is applied topically and incorporates...to placebo or one of three strengths of Femprox. They were required to use one application...
- NEXMED LICENSES FEMPROX TO CJ CORP. FOR SOUTH KOREA.
- Newspaper article from: Worldwide Biotech April 1, 2004 700+ words
...pharmaceuticals companies in South Korea, has licensed Femprox for Korea. Femprox is NexMed's proprietary cream treatment for female...develop and obtain regulatory approval to market Femprox(r) in South Korea, and NexMed, through its licensing...
- NexMed announces positive Femprox study results at AUA Annual Meeting in San...
- News wire article from: Asia Africa Intelligence Wire May 23, 2005 700+ words
...efficacy and safety of three strengths of the Femprox cream in pre-menopausal and post-menopausal...female sexual arousal disorder (FSAD). Femprox is applied topically and incorporates...to placebo or one of three strengths of Femprox. They were required to use one application...
- Femprox Demonstrated Positive Results in Female Sexual Arousal Disorder Study.
- Press release article from: Business Wire December 1, 1999 700+ words
...OTC BB: NEXM) announced today that its Femprox cream, incorporating alprostadil (prostaglandin...aroused with normal sexual stimulation. The Femprox cream is a promising treatment under development...commented, "The results indicate that the Femprox cream may also have applications in diagnosing...
- Femprox Data Published in Journal of Sex and Marital Therapy.
- Press release article from: PR Newswire October 2, 2001 700+ words
...system, today announced that data from a Femprox(TM) study conducted at the UMDNJ Robert...the Journal of Sex and Marital Therapy. Femprox(TM) is NexMed's proprietary cream...completed its Phase 1 clinical program for Femprox(TM), and initiated a Phase 2 study...
- NexMed to Initiate 400 Femprox(R) Clinical Study in China For Female Sexual...
- Press release article from: PR Newswire March 2, 2004 700+ words
...initiate a 400-patient Phase 3 study for Femprox(R) in China. The design of this study...and will test the efficacy and safety of Femprox(R) cream in patients diagnosed with female sexual arousal disorder (FSAD). Femprox(R), recently profiled on CBS 20...
- NexMed Closes Enrollment for 400 Patient Femprox(R) Study.
- Press release article from: PR Newswire November 15, 2004 700+ words
- Femprox featured in Forbes article - NexMed, Inc...enrollment for its 400-patient study for Femprox(R) in China. The study is double...designed to test the efficacy and safety of Femprox(R) cream in women diagnosed with female...
Source: HighBeam Research, Company to launch Femprox clinical study in China.